ResMed Inc.
RMD · NYSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.72 | 2.01 | 2.45 | 0.62 |
| FCF Yield | 4.39% | 4.68% | 1.74% | 0.64% |
| EV / EBITDA | 19.60 | 18.34 | 24.60 | 26.57 |
| Quality | ||||
| ROIC | 19.56% | 17.77% | 15.31% | 18.29% |
| Gross Margin | 59.36% | 56.67% | 55.78% | 56.57% |
| Cash Conversion Ratio | 1.25 | 1.37 | 0.77 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.81% | 9.40% | 9.72% | 6.56% |
| Free Cash Flow Growth | 29.18% | 130.00% | 186.66% | -68.53% |
| Safety | ||||
| Net Debt / EBITDA | -0.19 | 0.41 | 1.00 | 0.55 |
| Interest Coverage | 133.66 | 28.88 | 23.89 | 44.83 |
| Efficiency | ||||
| Inventory Turnover | 2.25 | 2.47 | 1.87 | 2.09 |
| Cash Conversion Cycle | 183.63 | 170.33 | 226.54 | 196.09 |